Molecular Diagnosis and Risk Stratification of Sepsis in India

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

550 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-12-06

Study Completion Date

2021-06-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background: Globally, sepsis is common with an estimated population incidence of 437 cases per 100, 000 person-years and acute mortality of 26%, one of the few major medical conditions whose incidence and resulting mortality continues to rise. However, true burden is likely significantly higher as a recent meta- analysis could find no data from LMIC where 87% of the world's population resides.

Objective: Generate new knowledge that will eventually provide rapid and accurate information about an individual patient suffering from sepsis (or critical illness), including which type of microorganism is responsible for the infection and the severity and stage of the patient's immune response.

Methods: MARS-India will be a prospective longitudinal, single-centre observational study, conducted in mixed ICU's of a \>2000 bedded tertiary teaching hospital in Manipal, India. The investigators will recruit to three groups- sex and age-matched healthy volunteers (n=150) and patients diagnosed with sepsis/septic shock or non-infectious ICU admissions such as severe trauma, severe burns and patients admitted to ICU after major surgery (n=400). The investigators have optimised a workflow to follow and describe the immunoinflammatory status of septic patients (as well as severe trauma/burn and major surgery) during the first 6 months after their initial injury. At fixed time points the investigators will collect blood in PaxGene, heparin, citrate and EDTA tubes in addition to routine bloods and microbiological samples. Rectal swabs and stool will also be taken for microbiome analysis. Immune functional tests will be performed to determine whole-blood cytokine/chemokine production in response to ex-vivo stimulation using an 8-panel assay. Additionally, complete immunophenotyping using flow cytometry including HLA-DR expression and lymphocyte subsets will be obtained.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Molecular Diagnosis and Risk Stratification of Sepsis

NCT01905033

Sepsis

UNKNOWN

Molecular Subtype-Specific Mechanisms and Therapeutic Strategies in Sepsis

NCT06287684

Sepsis Septic Shock

RECRUITING

European Prospective Bloodstream Infection Cohort

NCT07082322

Bloodstream Infection

NOT_YET_RECRUITING

Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room

NCT06178822

Sepsis Septic Shock Sepsis, Severe +4 more

RECRUITING

The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis

NCT03314831

Sepsis Syndrome Systemic Inflammatory Response Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

New sepsis 3.0 definition has for the first time included a dysregulated host response to infection as the cause of organ dysfunction, however, sepsis remains a highly heterogeneous syndrome without an accepted definition of what constitutes a dysregulated host response. The field is only now realising that inclusion of specific characteristics of the host response (transcriptomic or immunological profiles) facilitate stratification of patients with sepsis into subgroups (endotypes), allowing for prognostic enrichment and targeted therapeutic intervention.

Unfortunately, new guidelines continue to ignore the role of pathogens, virulence, sites of infection and lower-socio-economic settings. Additionally, it remains to be seen whether parasitic, viral and fungal conditions, common in LMIC, should be lumped with bacterial infections in the definition of sepsis. MARS -India will allow the investigators to compare these parameters and those of multi-drug resistant (MDR) pathogens on the impact of the host response and outcomes in sepsis. Not least develop an accurate temporal association of endotypes and detailed understanding of the immune suppressed phenotype. A functional immunology approach throughout and correlations with changes in the gut microbiome will further fortify our understanding of sepsis pathophysiology to help establish a 'sepsis fingerprint' and framework for novel interventions in future. Epidemiology data in itself will considerably heighten our understanding towards a global perspective on sepsis.

Furthermore, little guidance is offered in the Surviving Sepsis Guidelines toward optimal management of the seemingly cured post-acute sepsis patient, who is commonly readmitted with an infection or worse has a significantly reduced life expectancy (\>40% 1yr mortality in some studies). MARS-India will also aim to establish the burden of this stage of sepsis in a LMIC setting and study the underpinning pathophysiology in more detail to establish groundwork in uncovering pathways for future therapeutic targeting.

It is apparent that biomarkers reflecting activity of targetable immunological pathways will be of paramount importance in managing the septic patient in future.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Septic Shock Sepsis Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Septic/septic shock patients

Patients with underlying confirmed or probable cause of infection leading to sepsis or septic shock will form the active group of interest.

No interventions assigned to this group

Non-septic/sterile inflammation patients

Patient with severe trauma, severe burns and patients admitted to ICU after major surgery or pancreatitis. Active comparator group.

No interventions assigned to this group

Healthy control patients

Active comparator group.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients aged 18 years and over in the intensive care units of Kasturba Hospital, Manipal (and meeting the study population definitions below)
* Sepsis - defined as the presence of infection diagnosed within 24 hours of ICU admission with probable or definite likelihood, accompanied by organ dysfunction represented by an increase in the Sequential Organ Failure Assessment (SOFA) score of 2 points or more. Septic shock is defined as per the recent Sepsis 3.0 consensus guidelines.
* Serious trauma within 24 hours, with patient directly admitted to ICU (injury severity score (ISS) \>15).
* Severe burns (total surface area burned \>30%).
* Major surgery or pancreatitis/non-infectious inflammation.

Exclusion Criteria

* Pregnant or breast-feeding women
* Patients with a 'withdrawal of care' decision at time of inclusion
* Patients whose anticipated duration of hospitalisation in ICU is estimated \<48 hours
* Extra-corporeal circulation in the month preceding inclusion in the case of cardiac surgery
* Patient with restricted liberty or under legal protection
* Expected lifespan \<3 months due to pre-existing comorbidities
* Blood transfusion \>4 units in past week
* Second admission to ICU or previous enrolment in study (within same hospital admission)
* Transfer from other hospital ICU (if greater than 24hrs in total)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

W. J. Wiersinga, MD

Professor of Medicine, Chair division of Infectious Diseases and head of infectious diseases research group at the centre for experimental and molecular medicine (CEMM)

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chiranjay Mukhopadhyay, MD, Phd

Role: PRINCIPAL_INVESTIGATOR

Associate Dean and Professor Department of Microbiology, KMC Manipal

Willem Joost Wiersinga, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Professor of Medicine, Chair Devision of Infectious Diseases and head of infectious diseases research group at the centre for experimental and molecular medicine (CEMM), Amsterdam UMC (AMC)